The battle for Genzyme begins
This article was originally published in Scrip
Executive Summary
In today’s difficult business environment, with patent expiries looming and emerging markets assuming ever-greater importance, many pharma firms are turning to mergers and acquisitions as a way of providing some stability and at the same time adding some value to their companies.